Pfizer Begin Period Cash Flow vs Free Cash Flow Analysis

PFE Stock

11.78 0.04 0.34%

Pfizer financial indicator trend analysis is much more than just breaking down Pfizer Inc CDR prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pfizer Inc CDR is a good investment. Please check the relationship between Pfizer Begin Period Cash Flow and its Free Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc CDR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Begin Period Cash Flow vs Free Cash Flow

Begin Period Cash Flow vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pfizer Inc CDR Begin Period Cash Flow account and Free Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Pfizer's Begin Period Cash Flow and Free Cash Flow is 0.78. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Pfizer Inc CDR, assuming nothing else is changed. The correlation between historical values of Pfizer's Begin Period Cash Flow and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Pfizer Inc CDR are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Begin Period Cash Flow i.e., Pfizer's Begin Period Cash Flow and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.78

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Pfizer's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pfizer Inc CDR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc CDR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 13th of December 2024, Selling General Administrative is likely to grow to about 15 B, though Tax Provision is likely to grow to (1.1 B).

	2021	2022	2023	2024 (projected)
Gross Profit	50.5B	66.0B	33.5B	49.0B
Total Revenue	81.3B	100.3B	58.5B	71.0B

Gross Profit Total Revenue

Pfizer fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Net Receivables	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Long Term Investments	Short Long Term Debt
Total Assets		0.77	0.94	0.92	-0.89	0.86	0.66	0.92	0.9	0.56	0.95	0.93	0.81	0.82	0.14	0.7	-0.43	-0.02	0.73	0.93	-0.64	0.28	0.93	0.99	0.55	-0.15
Other Current Liab	0.77		0.84	0.87	-0.88	0.93	0.11	0.83	0.84	0.35	0.62	0.85	0.56	0.4	0.17	0.12	-0.32	0.52	0.22	0.85	-0.72	0.62	0.56	0.66	0.64	-0.57
Total Current Liabilities	0.94	0.84		0.87	-0.82	0.85	0.57	0.88	0.83	0.47	0.85	0.86	0.81	0.68	0.27	0.6	-0.38	0.16	0.57	0.84	-0.61	0.23	0.86	0.9	0.56	-0.08
Total Stockholder Equity	0.92	0.87	0.87		-0.89	0.9	0.33	0.98	0.96	0.28	0.83	0.98	0.75	0.56	0.12	0.39	-0.39	0.21	0.42	0.9	-0.68	0.43	0.7	0.86	0.56	-0.42
Other Liab	-0.89	-0.88	-0.82	-0.89		-0.98	-0.38	-0.89	-0.83	-0.59	-0.83	-0.91	-0.68	-0.67	0.08	-0.4	0.57	-0.14	-0.54	-0.96	0.86	-0.65	-0.75	-0.83	-0.77	0.5
Net Tangible Assets	0.86	0.93	0.85	0.9	-0.98		0.31	0.9	0.82	0.5	0.8	0.92	0.72	0.58	-0.08	0.32	-0.52	0.21	0.43	0.92	-0.89	0.67	0.69	0.79	0.81	-0.5
Net Debt	0.66	0.11	0.57	0.33	-0.38	0.31		0.4	0.33	0.71	0.76	0.4	0.63	0.91	0.01	0.98	-0.24	-0.62	0.95	0.48	-0.24	-0.2	0.88	0.76	0.25	0.52
Retained Earnings	0.92	0.83	0.88	0.98	-0.89	0.9	0.4		0.9	0.28	0.88	0.98	0.84	0.58	0.03	0.46	-0.47	0.1	0.46	0.86	-0.73	0.38	0.73	0.89	0.63	-0.31
Accounts Payable	0.9	0.84	0.83	0.96	-0.83	0.82	0.33	0.9		0.29	0.76	0.92	0.6	0.57	0.31	0.39	-0.29	0.29	0.45	0.9	-0.51	0.35	0.7	0.84	0.36	-0.44
Cash	0.56	0.35	0.47	0.28	-0.59	0.5	0.71	0.28	0.29		0.61	0.37	0.36	0.86	-0.17	0.61	-0.25	-0.31	0.82	0.64	-0.51	0.38	0.75	0.59	0.5	-0.01
Non Current Assets Total	0.95	0.62	0.85	0.83	-0.83	0.8	0.76	0.88	0.76	0.61		0.89	0.9	0.88	-0.11	0.77	-0.43	-0.3	0.8	0.85	-0.71	0.28	0.93	0.98	0.64	-0.01
Non Currrent Assets Other	0.93	0.85	0.86	0.98	-0.91	0.92	0.4	0.98	0.92	0.37	0.89		0.83	0.63	-0.04	0.43	-0.34	0.08	0.48	0.9	-0.77	0.5	0.74	0.89	0.66	-0.37
Other Assets	0.81	0.56	0.81	0.75	-0.68	0.72	0.63	0.84	0.6	0.36	0.9	0.83		0.65	-0.23	0.64	-0.32	-0.31	0.56	0.63	-0.7	0.22	0.76	0.85	0.71	0.14
Long Term Debt	0.82	0.4	0.68	0.56	-0.67	0.58	0.91	0.58	0.57	0.86	0.88	0.63	0.65		-0.05	0.87	-0.3	-0.43	0.97	0.77	-0.49	0.17	0.95	0.88	0.44	0.13
Net Receivables	0.14	0.17	0.27	0.12	0.08	-0.08	0.01	0.03	0.31	-0.17	-0.11	-0.04	-0.23	-0.05		0.12	0.03	0.58	0.01	0.08	0.52	-0.52	0.14	0.09	-0.57	0.08
Good Will	0.7	0.12	0.6	0.39	-0.4	0.32	0.98	0.46	0.39	0.61	0.77	0.43	0.64	0.87	0.12		-0.37	-0.56	0.93	0.49	-0.2	-0.29	0.88	0.79	0.19	0.51
Common Stock Shares Outstanding	-0.43	-0.32	-0.38	-0.39	0.57	-0.52	-0.24	-0.47	-0.29	-0.25	-0.43	-0.34	-0.32	-0.3	0.03	-0.37		0.02	-0.34	-0.45	0.48	-0.14	-0.4	-0.4	-0.47	0.19
Short Term Investments	-0.02	0.52	0.16	0.21	-0.14	0.21	-0.62	0.1	0.29	-0.31	-0.3	0.08	-0.31	-0.43	0.58	-0.56	0.02		-0.53	0.13	0.05	0.22	-0.24	-0.18	-0.11	-0.6
Non Current Liabilities Total	0.73	0.22	0.57	0.42	-0.54	0.43	0.95	0.46	0.45	0.82	0.8	0.48	0.56	0.97	0.01	0.93	-0.34	-0.53		0.65	-0.34	-0.01	0.91	0.8	0.29	0.26
Inventory	0.93	0.85	0.84	0.9	-0.96	0.92	0.48	0.86	0.9	0.64	0.85	0.9	0.63	0.77	0.08	0.49	-0.45	0.13	0.65		-0.73	0.54	0.82	0.88	0.6	-0.46
Other Current Assets	-0.64	-0.72	-0.61	-0.68	0.86	-0.89	-0.24	-0.73	-0.51	-0.51	-0.71	-0.77	-0.7	-0.49	0.52	-0.2	0.48	0.05	-0.34	-0.73		-0.8	-0.51	-0.6	-0.98	0.45
Other Stockholder Equity	0.28	0.62	0.23	0.43	-0.65	0.67	-0.2	0.38	0.35	0.38	0.28	0.5	0.22	0.17	-0.52	-0.29	-0.14	0.22	-0.01	0.54	-0.8		0.11	0.2	0.74	-0.79
Total Liab	0.93	0.56	0.86	0.7	-0.75	0.69	0.88	0.73	0.7	0.75	0.93	0.74	0.76	0.95	0.14	0.88	-0.4	-0.24	0.91	0.82	-0.51	0.11		0.95	0.47	0.13
Net Invested Capital	0.99	0.66	0.9	0.86	-0.83	0.79	0.76	0.89	0.84	0.59	0.98	0.89	0.85	0.88	0.09	0.79	-0.4	-0.18	0.8	0.88	-0.6	0.2	0.95		0.52	-0.02
Long Term Investments	0.55	0.64	0.56	0.56	-0.77	0.81	0.25	0.63	0.36	0.5	0.64	0.66	0.71	0.44	-0.57	0.19	-0.47	-0.11	0.29	0.6	-0.98	0.74	0.47	0.52		-0.31
Short Long Term Debt	-0.15	-0.57	-0.08	-0.42	0.5	-0.5	0.52	-0.31	-0.44	-0.01	-0.01	-0.37	0.14	0.13	0.08	0.51	0.19	-0.6	0.26	-0.46	0.45	-0.79	0.13	-0.02	-0.31

Click cells to compare fundamentals

Pfizer Account Relationship Matchups

Pfizer fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	167.5B	154.2B	181.5B	197.2B	226.5B	199.2B
Other Current Liab	11.7B	12.1B	26.7B	23.4B	20.5B	19.6B
Total Current Liabilities	37.3B	25.9B	42.7B	42.1B	47.8B	41.7B
Total Stockholder Equity	63.1B	63.2B	77.2B	95.7B	89.0B	82.8B
Other Liab	29.9B	26.6B	22.6B	23.3B	21.0B	21.3B
Net Tangible Assets	(19.0B)	(14.7B)	2.8B	916M	1.1B	1.1B
Net Debt	50.8B	36.5B	35.1B	34.5B	68.0B	48.6B
Retained Earnings	97.7B	90.4B	103.4B	125.7B	118.4B	114.6B
Accounts Payable	3.9B	4.3B	5.6B	6.8B	6.7B	5.9B
Cash	1.3B	1.8B	1.9B	416M	2.9B	1.7B
Non Current Assets Total	134.7B	119.2B	121.8B	145.9B	183.2B	149.3B
Non Currrent Assets Other	4.5B	4.6B	7.7B	13.2B	12.5B	8.3B
Other Assets	18.0B	5.8B	8.2B	16.9B	19.4B	11.7B
Long Term Debt	36.0B	35.6B	34.8B	31.9B	60.5B	42.4B
Net Receivables	9.5B	7.9B	11.5B	11.0B	11.2B	11.4B
Good Will	58.7B	49.6B	49.2B	51.4B	67.8B	60.5B
Common Stock Shares Outstanding	5.5B	5.6B	5.6B	5.6B	5.6B	4.5B
Short Term Investments	8.5B	10.4B	29.1B	22.3B	9.8B	18.0B
Non Current Liabilities Total	66.7B	64.8B	61.3B	59.2B	89.4B	74.3B
Inventory	7.1B	8.0B	9.1B	9.0B	10.2B	9.3B
Other Current Assets	6.5B	3.6B	3.8B	5.0B	5.3B	4.9B
Other Stockholder Equity	(11.6B)	(5.3B)	(5.9B)	(8.3B)	(9.5B)	(10.0B)
Total Liab	104.0B	90.8B	104.0B	101.3B	137.2B	116.0B
Net Invested Capital	115.3B	101.5B	114.2B	130.5B	159.9B	133.1B
Long Term Investments	20.1B	20.3B	21.5B	15.1B	15.4B	17.4B
Short Long Term Debt	16.2B	2.7B	2.2B	2.9B	10.3B	5.8B
Total Current Assets	32.8B	35.1B	59.7B	51.3B	43.3B	49.9B
Capital Stock	485M	470M	473M	476M	478M	382.4M
Non Current Liabilities Other	6.3B	6.7B	9.7B	13.2B	16.5B	10.7B
Net Working Capital	(4.5B)	9.1B	17.0B	9.1B	(4.5B)	(4.2B)
Intangible Assets	35.4B	28.5B	25.1B	43.4B	64.9B	42.6B
Common Stock	468M	470M	473M	476M	547.4M	517.9M
Property Plant Equipment	14.3B	15.1B	17.7B	19.3B	22.2B	17.5B

Pair Trading with Pfizer

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.

Moving together with Pfizer Stock

0.74	AEMC	Alaska Energy Metals	Pair Corr
0.84	CMC	Cielo Waste Solutions Earnings Call This Week	Pair Corr

Moving against Pfizer Stock

0.84	MATE	Blockmate Ventures	Pair Corr
0.81	LQWD	LQwD FinTech Corp	Pair Corr

The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc CDR to buy it.

The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Pfizer Stock

Balance Sheet is a snapshot of the financial position of Pfizer Inc CDR at a specified time, usually calculated after every quarter, six months, or one year. Pfizer Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Pfizer and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Pfizer currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC